Source: CureToday articles
The FDA has accepted and granted priority review to an NDA for sevabertinib in previously treated HER2+ non-small cell lung cancer.
Recent Content
- Day 3: Top Takeaways From ASCO25
- NLA 2025: The Earlier LDL Cholesterol Is Lowered, the Greater the Cardiovascular Risk Reduction
- NLA 2025: Emerging Therapies Target Remnant Cholesterol to Address Residual Cardiovascular Risk
- NLA 2025: Practical Strategies for Identifying the Right Patient for Incretin Therapy
- Adjuvant Opdivo Combo Improves Survival Outcomes in Advanced Head and Neck Cancer
- Camizestrant and CDK4/6 Inhibition Benefits Outcomes in Breast Cancer Subgroups
- Tecentriq Plus Chemo Reduced Risk of Death vs Chemo Alone in dMMR Colon Cancer
- NLA 2025: Understanding the Impact of Omega-3 Fatty Acids on LDL Cholesterol
- Harnessing the Tumor Microenvironment for Enhanced Cancer Treatment
- NLA 2025: Exploring the Evidence Behind Omega-3 Fatty Acids for Cardiovascular Risk